A Phase 4 interventional study of Rivastigmine Transdermal Product and Sham in Depressive Disorder, sponsored by UMC Utrecht. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by UMC Utrecht · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.
Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 8th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Arkin · Sites in Netherlands
Ages 18–65
Universiteit Leiden · Sites in Netherlands
Ages 18–65
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 151 across the 16 interventional studies, 216 across the 2 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
UMC Utrecht is the lead sponsor of 364 studies on the registry; 81 are open to participants now.
UMC Utrecht has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022184Radboud University Medical CenterLifestyle Intervention for Symptoms of Depression wIth App Support in General Practice | 2026-11 |
| NCT05640089Maastricht University Medical CenterFMRI-neurofeedback in Depression | 2027-04-30 |
| NCT07950800ArkinFrom There Towards Now; Intervention for Jewish and Indonesian Post-war Generations | 2027-08-01 |
| NCT05551468Ggz Oost BrabantStayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths | 2027-11-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the beneficial effects of rivastigmine administration, and predict the treatment outcome with electroencephalography (EEG), in patients with severe depression treated with electroconvulsive therapy (ECT). The study has two main objectives:
Participants will be assessed by:
Researchers will compare patients with a depressive disorder treated with ECT receiving rivastigmine to placebo patches to see if rivastigmine reduces cognitive side effects.
Electroconvulsive therapy (ECT) is the most potent psychiatric treatment, with an effect size of 1.5 for severe and refractory unipolar and bipolar depression. ECT convincingly outperforms pharmacotherapy such as tricyclic antidepressants and monoamine oxidase inhibitors and any form of psychotherapy. Despite its outstanding performance in reducing depressive symptoms up to the point of full remission, it is used only marginally. One reason for its infrequent use may be that the response to ECT is largely unpredictable, while cognitive side-effects occur frequently.
In a previous study, the researchers found that multiple cognitive tests showed a significant decline immediately post-ECT, which resolved within 6 months after the last ECT session without further treatment. Even though cognitive side-effects are mostly short-lasting, both patients and doctors see this as a great drawback of ECT. If these disturbing side-effects could be prevented, more patients and psychiatrists would choose ECT as a treatment option. This would lead to a more effective treatment and hence shorter duration of chronic severe depression and improvement in quality of life, while costs for health care and loss of productivity would decrease. A potential way of ameliorating side effects, could be to add a cholinesterase inhibitor to ECT treatment. Rodent studies show that the loss of cholinergic fibers specifically correlated to the cognitive side effects of rodents after electroconvulsive stimulation (ECS). The researchers selected rivastigmine (a cholinesterase inhibitor) as a potential candidate in counteracting cognitive side effects induced by cholinergic fiber loss due to ECT. Rivastigmine patches are very well tolerated and widely used for Alzheimer's and Parkinson's dementia.
Tailoring treatment to patients that are likely to respond while cognitive side-effects are unlikely to occur, would be another important improvement for depressed patients. Currently, ECT outcome is unpredictable. Factors that favor response include older age, psychotic depression, shorter duration of the depressive episode, and smaller volumes of the dentate gyrus (a part of the hippocampus). However, these predictors do not provide enough accuracy to make individual response profiles. Accurately classifying specifically non-responders will prevent application of ineffective treatment with potential iatrogenic damage, while more accurately predicted response will increase the applicability of ECT as treatment option. A potentially powerful way that is easy to implement in the clinic is prediction of ECT response using resting state EEG characteristics in addition to clinical information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivastigmine, transdermal administration with a dosage of 4.6 and 9.6mg. The patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
Drug: Rivastigmine Transdermal Product
Non-active patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
Other: Sham
The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
The sham patches will be administered during the same period of time as the rivastigmine.
The effect of rivastigmine on scores of the verbal fluency test.
Changes in cognitive functioning as measured by scores on the Verbal fluency test, in which participants are asked to pronounce as many words (0 - infinity) as possible in 60 seconds in a certain category or starting with a certain letter. A higher score means a better outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
The effect of rivastigmine on scores of the Rey auditory verbal learning test
Changes in cognitive functioning as measured by scores on the Rey auditory verbal learning test, in which the assessor reads a list of of 15 words to the participant, and the participant is asked to repeat as many words as they remember. This is repeated 5 times (learning) and 15 minutes later the participant is asked how many words (0-15 words) they remember (memory). The scale ranges from 0-90 words in total. A higher score means a better outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
The effect of rivastigmine on changes in scores on the Montreal Cognitive Assessment
Changes in cognitive functioning as measured by scores on the Montreal Cognitive Assessment, that comprises of assessing multiple cognitive domains with a scoring scale of 0-30. A higher score means a better outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
The effect of rivastigmine on changes in scores on the Columbia University Autobiographical Memory Interview short form
Changes in cognitive functioning before, during and after treatment as measured by scores on the Columbia University Autobiographical Memory Interviewshort form. The subject's ability to remember the specific details originally provided during the pre-treatment interview is measured on a scale of 0-60 points. A higher score means a better outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in resting-state EEG peak frequency
To develop an outcome prediction model the investigators will use resting state EEG output in units of peak frequency
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Treatment response
Treatment response defined as 50% symptom reduction as measured with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome.
Time frame: Baseline
Treatment response
Treatment response defined as 50% symptom reduction as measured with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome.
Time frame: Within 72 hours after the first treatment session
Treatment response
Treatment response defined as 50% symptom reduction as measured with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome.
Time frame: Within 1 week after the last treatment session
Treatment response
Treatment response defined as 50% symptom reduction as measured with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome.
Time frame: At 3-months after the last treatment session
Remission
with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome. Remission as measured by a score of \<7.
Time frame: Baseline
Remission
with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome. Remission as measured by a score of \<7.
Time frame: Within 72 hours after the first treatment session
Remission
with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome. Remission as measured by a score of \<7.
Time frame: Within 1 week after the last treatment session
Remission
with the Hamilton Depression Scale (17-item version), that comprises of 17 questions on depressive symptoms measured on a scale of 0-52 points. A higher score means a worse outcome.Remission as measured by a score of \<7.
Time frame: At 3-months after the last treatment session
Quality of life of patients assessed with the European Quality of Life Five Dimensions with Five Levels (Euro-QoL-5D-5L)
The assessment of the quality of life of patients during the study, it comprises of 5 questions, measured on a scale of 5-25. A higher score means a worse outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Quality of life of patients assessed with the visual analog scale of the European Quality of Life Five Dimensions with Five Levels (Euro-QoL-5D-5L)
The assessment of the quality of life of patients during the study. The instrument includes a visual analog scale (VAS) anchored by 0 (worst imaginable health) and 100 (best imaginable health). A higher score means a better outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in the global assessment of disability using the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 12 item version
The assessment of global disability of the patients during the study, measured on a scale of 12-60. A higher score means a worse outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in peak amplitude measured with selective attention EEG task
The selective attention tasks measures behavioral outcomes by hits/misses/false alarms.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in behavioral outcome measured with the selective attention EEG task
The selective attention task measures behavioral outcomes by hits/misses/false alarms.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in processing negativity measured with the selective attention EEG task
The selective attention task measures behavioral outcomes by hits/misses/false alarms.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in mismatch negativity measures (amplitude, latency and duration) obtained with the MisMatch Negativity Paradigm during an EEG recoding
The mismatch negativity task measures event-related potentials by EEG and the Mismatch Negativity Paradigm
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Change in subjective feeling of memory impairment on the Subjective Assessment of Memory Impairment (SAMI) questionnaire
The Subjective Assessment of Memory Impairment is a questionnaire that comprises of two questions of which the first question concerns the subjective feeling of memory point, rated on a 10-point likert scale, and is rated from 0 no impairment, to 10 severe impairment. A higher score means a worse outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Change in impact of cognitive adverse events on the Subjective Assessment of Memory Impairment (SAMI) questionnaire
The Subjective Assessment of Memory Impairment is a questionnaire that comprises of two questions of which the second question concerns the impact of cognitive adverse events, on a 5-point likert scale, rated from 1 no complaints, to 5 severe complaints. A higher score means a worse outcome.
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in the Expectation of response form
The likelihood that they will recover questioned by a scale with a range from -5 (negative effect expected) to 5 (positive effect expected)
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in Free speech using the PRAAT task
The researchers will collect free speech data (5 minutes of free speech) to study language characteristics of responders (remitters) and non-responders (non-remitters).
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Changes in DNA methylation
The researchers will collect 6ml blood samples for DNA methylation levels
Time frame: Baseline, within 72 hours after the first treatment session, within 1 week after the last treatment session and at 3-months after the last treatment session
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Dec 2025, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.